Beginner-friendly– category –

In this final deep-dive of our beginner-friendly bispecific antibody series, we explore the historical trajectory of bispecific antibody (BsAb) technology. In this final deep-dive of our beginner-friendly bispecific antibody series, we e...

In this final volume, we summarize the latest developments in bispecific antibody drug R&D by leading biotech and pharma companies, as well as major approvals over the past year in the US and EU. In this final volume, we summarize th...

Even among bispecific antibody drugs, the pharmacological behavior in the body can vary significantly depending on the structural modality. Even among bispecific antibody drugs, the pharmacological behavior in the body can vary significa...

In this third installment of our Beginner-Friendly Bispecific Antibody Drug series, we delve into the crucial question: “Which targets should be selec In this third installment of our Beginner-Friendly Bispecific Antibody Drug series, we...

In this second installment of our series on bispecific antibody drugs, we delve into the diverse structural formats that define the field. In this second installment of our series on bispecific antibody drugs, we delve into the diverse s...

Introduction: Why Are Bispecific Antibody Drugs Gaining Attention? In recent years, bispecific antibody drugs (BsAbs) have garnered increasing attention in the treatment of cancer, autoimmune diseases, and infectious diseases. In recent ...

Global Strategies Shaping the Future of in vivo CAR-T Development Throughout this series, we have explored the cutting-edge developments of in vivo CAR-T therapy in an accessible way for beginners. Throughout this series, we have explore...

Key Figures Shaping the Future of in vivo CAR-T This series aims to provide a clear and accessible overview of the latest advancements in in vivo CAR-T therapies, especially for beginners. This series aims to provide a clear and accessib...

In vivo CAR-T therapy has rapidly emerged as a promising next-generation cancer treatment. In vivo CAR-T therapy has rapidly emerged as a promising next-generation cancer treatment. However, realizing its full potential requires overcomi...

In previous installments, we've explored the fundamentals of CAR-T, the features of the in vivo model, gene delivery strategies, target antigens, and intracellular signaling. In previous installments, we've explored the fundamentals of C...

For in vivo CAR-T cells to attack cancer persistently and effectively, the structure of the CAR itself is critical. For in vivo CAR-T cells to attack cancer persistently and effectively, the structure of the CAR itself is critical. In pa...

In this third installment of our introductory series on in vivo CAR-T, we focus on a vital component for realizing safe and effective therapy: the design of CAR expression. In this third installment of our introductory series on in vivo ...

In the first installment of our series, we introduced the revolutionary CAR-T cell therapy through the moving story of Emily Whitehead. In the first installment of our series, we introduced the revolutionary CAR-T cell therapy through th...

CAR-T cell therapy has emerged as a groundbreaking treatment that specifically targets cancer cells. Among its forms, the “in vivo type” CAR-T—where the therapeutic process happens inside the body—is gaining attention as a next-generatio...

Over the past few years, the landscape of Antibody-Drug Conjugates (ADCs) has undergone a dramatic transformation, shifting from a niche therapeutic approach to a central pillar of oncology innovation. Over the past few years, the landsc...

Antibody-drug conjugates (ADCs) deliver highly potent cytotoxic agents specifically to cancer cells, representing a breakthrough in targeted therapy. This article explains the final stage of ADC function—how the linker system releases th...

In Antibody-Drug Conjugates (ADCs), antibodies serve as targeting agents that deliver drugs to cancer cells. This article focuses on the "Variable Region," the key structure that enables antibodies to specifically recognize cancer antige...

Antibody-drug conjugates (ADCs) are next-generation therapeutics gaining attention, especially in oncology. Antibody-drug conjugates (ADCs) are next-generation therapeutics gaining attention, especially in oncology. In this second part, ...

Summer Special｜Beginner-Friendly Intro Series Vol.2 (Part 1)What Are Antibodies? The Origin Story of ADCs – A Precision Cancer Weapon Welcome to Part 1 of our Summer Special Beginner Series Vol.2 on Morningglorysciences.This time, we’ll...

Summer Special｜Beginner-Friendly Intro Series Vol.1 (Part 2)Are They Safe? Global Competition and the Future of Anti-Obesity Drugs In Part 1, we explored what anti-obesity medications are, how GLP-1 works, and the key players in the cur...